ABOUT US

Andrew Butler-Cassar began with Lloyds Private Banking in 1994 as a portfolio manager and client advisor in its UHNW team. In 2002, he moved to the private client division of Williams de Broe, where he oversaw funds grow from £250m to £8b. He was appointed Head of the Investec Private Office in 2014. Andrew joined Brown Shipley Private Bank in 2019, where he created and oversaw the Private Banking Team. Most recently, Andrew worked as Director at The Hottinger Group, where he advised clients and families.

Nikos Anastasiades has almost 20 years of experience in regulatory compliance function units within the financial markets. He is a holder of an AML Certificate, an Advanced Certificate and a Certificate A1 of the Central Bank of Greece and HCMC, as well as an Equities Trader Certificate (ATHEX). Previous experience includes employment at various compliance managerial positions in listed companies (Lamda Development SA), private banking (Société Générale Bank & Trust) and asset management regulated entities (Argus Stockbrokers Ltd). He is a holder of a BSc in Economics, a BSc in Business Economics and an MA in International Business from the UK. He has extensive experience with a proven track record in regulatory framework with strong expertise in compliance advisory.

Anatoly Fedorov is a Portfolio Manager and the Head of Equities of Signet Group. Anatoly manages Signet’s global leaders portfolio and has experience working with Long-short Equity and Merger Arbitrage strategies. Prior to joining the Investment Manager in February 2018, he worked as a Vice President at J.P. Morgan in EMEA Diversified Industrials Practice. Here he conducted financial and valuation analysis, execution, project management and due diligence on large scale M&A transactions (for example from 2016: Philips Lighting IPO and SGD Pharma sell-side). Prior to his employment at J.P. Morgan, Anatoly was an equity research analyst at Genesis Investment Management. During his time there, he executed financial analysis, valuation and communication with corporate management for emerging markets.

Natalia Kolvalevskaya has 14 years of professional experience in the financial industry in London, both in investment banking and investment management. Prior to joining Signet, Natalia invested in private healthcare companies in Europe and in the US. She also founded an investment platform for early-stage life sciences ventures supporting medical innovation. She has extensive experience sourcing, originating and investing across early- to late-stage biotech companies both private and public. Natalia started her career at Citi in London in Capital Markets Origination. She then moved on to Global Markets at VTB Capital London, Mizuho International and UBS Investment Bank where her expertise spanned various products and asset classes with a focus on global emerging markets and European institutional investors such as pension funds, hedge funds and real money investors. Natalia holds a BSc in Biochemistry from Imperial College London, MSc Management in Pharma from the London School of Economics and an MEng in Food Engineering from Moscow State University of Applied Biotechnology. Natalia is fluent in English, Russian, Italian, French and has some conversational German.

Tushar Jian has 11 years of experience as an equity research analyst with a strong knowledge of analysing financial statements, corporate strategy and industry trends to identify medium- to long-term investment opportunities. He has a strong analytical and quantitative background (MBA from INSEAD, Computer Science from NUS, CFA) which is complemented with around 10 years of equity research experience at Goldman Sachs and the Bank of America Merrill Lynch.

Yiyi Jiang is an Equity Analyst covering the healthcare sector at Signet Capital Management. Prior to joining Signet in 2021, Yiyi was a Senior Equity Analyst at HSBC Asset Management for more than six years covering Healthcare and Tech sectors in developed markets. Before that, she worked as Equity Analyst at Lombard Odier Asset Management and Strategic Investment Advisors. Following her BA in Finance from Renmin University, Yiyi completed her Masters in Economics from Yale University and PhD in Finance from IE Business School.

Prior to joining Signet Management, Dr. Robert Shore was lead biotechnology analyst at Redburn, Europe’s largest independent equity research brokerage. This followed several years as a postdoctoral research fellow in molecular biology at Harvard Medical School, where he developed a model for the ZIKA virus through CRISPR gene editing. Robert holds an MSc in Bioscience Technology, a PhD in Neurogenetics from the University of St Andrews’ School of Medicine and is currently an MBA candidate at the University of Cambridge’s Judge Business School.

Robert Marquardt was the Founder of the Signet Group of Companies in the early 1990s and is today Chairman of Signet Wealth Management. Robert, as hedge fund CIO, has managed and advised on investment strategy and hedge fund / alternative investment selection globally since 1994. Through Signet’s offices in Switzerland, London and Hong Kong the group managed and advised on hedge fund selection with an asset level in excess of $3.5 billion at the peak. Prior to founding Signet, Robert was the Managing Director of Chase Private Banking in Luxembourg and a Credit Officer of Chase Manhattan Bank in the Middle East during a 12-year career at the Chase. Robert has deep knowledge of the opportunities and risks in different global economic and market environments across fixed income, equity, commodity and currency strategies through different economic cycles and holding structures.

Daria Vodyasova gained an Honours Degree in Economics and Sociology, followed by an M.A. Degree in the Psychology of Personnel Management at the State Education Institution of Higher Professional Education. Today, she heads up Signet’s investor relations and client services, supporting our customers across our full product range.